Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Type B3 Thymoma and Thymic Carcinoma
NCT03134118Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2018
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in thymoma and thymic carcinoma (TC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression Free Survival Rate at 6 months. Started Apr 2018; status: active, not recruiting.
02
Drugs
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT03134118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03134118.